BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

535 related articles for article (PubMed ID: 21087355)

  • 1. Concomitant irritable bowel syndrome is associated with failure of step-down on-demand proton pump inhibitor treatment in patients with gastro-esophageal reflux disease.
    Wu JC; Lai LH; Chow DK; Wong GL; Sung JJ; Chan FK
    Neurogastroenterol Motil; 2011 Feb; 23(2):155-60, e31. PubMed ID: 21087355
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distinct clinical characteristics between patients with nonerosive reflux disease and those with reflux esophagitis.
    Wu JC; Cheung CM; Wong VW; Sung JJ
    Clin Gastroenterol Hepatol; 2007 Jun; 5(6):690-5. PubMed ID: 17481961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical, but not oesophageal pH-impedance, profiles predict response to proton pump inhibitors in gastro-oesophageal reflux disease.
    Zerbib F; Belhocine K; Simon M; Capdepont M; Mion F; Bruley des Varannes S; Galmiche JP
    Gut; 2012 Apr; 61(4):501-6. PubMed ID: 21997546
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of proton pump inhibitor failure in non-erosive reflux disease: A study with impedance-pH monitoring and high-resolution manometry.
    Shi Y; Tan N; Zhang N; Xiong L; Peng S; Lin J; Chen M; Xiao Y
    Neurogastroenterol Motil; 2016 May; 28(5):674-9. PubMed ID: 26768192
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PPI therapy is equally effective in well-defined non-erosive reflux disease and in reflux esophagitis: a meta-analysis.
    Weijenborg PW; Cremonini F; Smout AJ; Bredenoord AJ
    Neurogastroenterol Motil; 2012 Aug; 24(8):747-57, e350. PubMed ID: 22309489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of long-term PPI treatment on producing bowel symptoms and SIBO.
    Compare D; Pica L; Rocco A; De Giorgi F; Cuomo R; Sarnelli G; Romano M; Nardone G
    Eur J Clin Invest; 2011 Apr; 41(4):380-6. PubMed ID: 21128930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence and clinical characteristics of refractoriness to optimal proton pump inhibitor therapy in non-erosive reflux disease.
    Ribolsi M; Cicala M; Zentilin P; Neri M; Mauro A; Efthymakis K; Petitti T; Savarino V; Penagini R
    Aliment Pharmacol Ther; 2018 Nov; 48(10):1074-1081. PubMed ID: 30294924
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of risk factors and clinical responses to proton pump inhibitors in patients with erosive oesophagitis and non-erosive reflux disease.
    Lee ES; Kim N; Lee SH; Park YS; Kim JW; Jeong SH; Lee DH; Jung HC; Song IS
    Aliment Pharmacol Ther; 2009 Jul; 30(2):154-64. PubMed ID: 19392871
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Race affects healing of erosive oesophagitis in patients treated with proton pump inhibitors.
    Sharma P; Johnson DA; Monyak JT; Illueca M
    Aliment Pharmacol Ther; 2011 Aug; 34(4):487-93. PubMed ID: 21682754
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between symptom response and esophageal pH level on standard dose of esomeprazole treatment for gastroesophageal reflux disease.
    Peng S; Xiong LS; Xiao YL; Wang AJ; Lin JK; Hu PJ; Chen MH
    Chin Med J (Engl); 2010 Aug; 123(15):2012-7. PubMed ID: 20819534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proton pump inhibitor responders who are not confirmed as GERD patients with impedance and pH monitoring: who are they?
    de Bortoli N; Martinucci I; Savarino E; Bellini M; Bredenoord AJ; Franchi R; Bertani L; Furnari M; Savarino V; Blandizzi C; Marchi S
    Neurogastroenterol Motil; 2014 Jan; 26(1):28-35. PubMed ID: 23992024
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathogenesis of proton-pump inhibitor-refractory non-erosive reflux disease according to multichannel intraluminal impedance-pH monitoring.
    Kohata Y; Fujiwara Y; Machida H; Okazaki H; Yamagami H; Tanigawa T; Watanabe K; Watanabe T; Tominaga K; Arakawa T
    J Gastroenterol Hepatol; 2012 Apr; 27 Suppl 3():58-62. PubMed ID: 22486873
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of proton-pump inhibitor treatment on symptoms and quality of life in GERD patients depends on the symptom-reflux association.
    Aanen MC; Weusten BL; Numans ME; de Wit NJ; Samsom M; Smout AJ
    J Clin Gastroenterol; 2008; 42(5):441-7. PubMed ID: 18344896
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eight weeks of esomeprazole therapy reduces symptom relapse, compared with 4 weeks, in patients with Los Angeles grade A or B erosive esophagitis.
    Hsu PI; Lu CL; Wu DC; Kuo CH; Kao SS; Chang CC; Tai WC; Lai KH; Chen WC; Wang HM; Cheng JS; Tsai TJ; Chuah SK
    Clin Gastroenterol Hepatol; 2015 May; 13(5):859-66.e1. PubMed ID: 25245625
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gastroesophageal reflux disease in primary care: using changes in proton pump inhibitor therapy as an indicator of partial response.
    Ruigómez A; Johansson S; Wernersson B; Fernández Cantero O; García Rodríguez LA
    Scand J Gastroenterol; 2012 Jul; 47(7):751-61. PubMed ID: 22519917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Laryngopharyngeal reflux: prospective cohort study evaluating optimal dose of proton-pump inhibitor therapy and pretherapy predictors of response.
    Park W; Hicks DM; Khandwala F; Richter JE; Abelson TI; Milstein C; Vaezi MF
    Laryngoscope; 2005 Jul; 115(7):1230-8. PubMed ID: 15995512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of three different dosages of esomeprazole in the long-term management of reflux disease: a prospective, randomized study, using the wireless Bravo pH system.
    Vasiliadis KV; Viazis N; Vlachogiannakos J; Sgouros SN; Stefanidis G; Archimandritis A; Karamanolis DG
    Am J Gastroenterol; 2010 Feb; 105(2):308-13. PubMed ID: 19809412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The influence of co-morbid IBS and psychological distress on outcomes and quality of life following PPI therapy in patients with gastro-oesophageal reflux disease.
    Nojkov B; Rubenstein JH; Adlis SA; Shaw MJ; Saad R; Rai J; Weinman B; Chey WD
    Aliment Pharmacol Ther; 2008 Mar; 27(6):473-82. PubMed ID: 18194508
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Partial symptom-response to proton pump inhibitors in patients with non-erosive reflux disease or reflux oesophagitis - a post hoc analysis of 5796 patients.
    Bytzer P; van Zanten SV; Mattsson H; Wernersson B
    Aliment Pharmacol Ther; 2012 Oct; 36(7):635-43. PubMed ID: 22860764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Diagnosis of gastroesophageal reflux disease-related noncardiac chest pain].
    Zheng J; Du ZM; Chen MH; Lin JK; Hu PJ
    Zhonghua Yi Xue Za Zhi; 2008 May; 88(20):1390-3. PubMed ID: 18953876
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.